Persistent pricing pressure in US generics and API
Pricing pressure in US generics and API businesses persisted during the quarter, partially offset by cost efficiencies.
high · management_commentaryAlembic Pharmaceuticals Limited — Q3 FY26
Alembic Pharmaceuticals reported Q3 FY26 revenue of ₹2,876 crore, up 11% YoY, driven by volume expansion and new launches, partially offset by US generics and API pricing pressure.
neutral
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
India branded business underperformance
India branded business grew only 6% YoY, below market growth, and management has not provided a clear timeline for improvement beyond Q1 FY27.
medium · analyst_questionPivya launch margin drag
The branded product Pivya launch will impact near-term profitability, with management unable to quantify the margin impact.
medium · analyst_questionDependence on injectable and complex generics for future growth
Management expects injectables and complex generics to drive US growth over the next 2-3 years, but approvals and ramp-up remain uncertain.
medium · data_observation